Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

and diluted

40,916,66632,828,69737,417,77522,909,802ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)December 31,
2011December 31,
2010Cash and cash equivalents

$
5,624$
40,030Short term investments

$
,746$
23,351Total assets

$
9,493$
5,263Total current liabilities, excluding current portion of notes payable

$
26,078$
8,005Total notes payable

$
24,331$
8212;Deficit accumulated during development stage

$   (200,979)$   (105,644)Total shareholders' equity

$
9,084$
57,258Common shares outstanding

40,933,35432,853,032
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... (CFO), has notified the Board of Directors of his decision to ... opportunity as CFO of Severn Trent plc.  James will leave Shire ... a search for a new CFO immediately. Flemming Ornskov, ... and lead a high-quality finance team at Shire. We are very ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
(Date:10/19/2014)... N.Y. , Oct. 19, 2014  Henry Schein, ... provider of health care products and services to office-based ... it has invested in Iwase Dental Supply, Inc., a ... in Japan.  The transaction marks Henry Schein,s entrance into ... largest dental market, and increases to 28 the number ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
... and OXFORD, England, Nov. 18, 2011   EUSA Pharma, a ... supportive care and critical care, today announced that ... approved its orphan drug ERWINAZE™ (asparaginase Erwinia ... leukemia (ALL) in patients with hypersensitivity to ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 2EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 4
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... 2014 Myoderm announced ... Director of their CentralSource service. Matthew ... innovative turnkey drug sourcing, distribution, and management service ... 12 years of industry experience, in both business ... peak of their international success to help clients ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... in US are not getting ample amounts of a nutrient ... development.// ,A new study sponsored by the National ... the top universities in America has suggested that the women ... is required to promote normal fetal brain development. ...
... deleterious effect on young, developing brains, according to researchers ... linked to lower IQ scores later in life. // ... diabetes, high cholesterol and hypertension is a well documented ... genetics at the University of Florida said, 'We're postulating ...
... after they received blood transfusion thought to be contaminated ... been// infected in the last few months in various ... died were all younger than two years old," a ... suspected donors who are thought to have HIV.HIV/AIDS infection ...
... the University of Virginia Health System have found that ... drive better when they took// OROS methylphenidate (OROS MPH), ... (se-AMPH ER). The findings, which reinforce the use of ... ADHD, will appear in the Sept. issue of Pediatrics. ...
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... in children that can often be disabling and one ... from school could mainly be due to their genetic// ... Medicine (Department of Psychological Medicine), in a genetic study ... usually occur together, they are of different genetic and ...
Cached Medicine News:Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 2Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 3Health News:Obesity Takes its Toll on IQ of Toddlers 2Health News:Not All ADHD Drugs Are Equal 2
Listeria Enrichment Broth...
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
... units Penicillin/25,000 ug Streptomycin ... Reagent and Buffer products ... with cGMP regulations and ... to assure compatibility. , ...
...
Medicine Products: